ÀÌ»óÈÆ ¸íÀÇ

ȯÀÚÀÇ ¸¶À½À» ¸ÕÀú ÀÌÇØÇÏ´Â °­Á÷ôÃß¿° ¸íÀÇ

ÀÌ»óÈÆ ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú
  • Àü¹®ºÐ¾ß
    °­Á÷¼ºÃ´Ãß¿°, ·ù¸¶Æ¼½º°üÀý¿°, ·çǪ½º, ÀÚ°¡¸é¿ªÁúȯ

°­µ¿°æÈñ´ëº´¿ø ·ù¸¶Æ¼½º³»°ú Àü¹®ÀÇ·Î ÁÖ Áø·á ºÐ¾ß´Â °­Á÷ôÃß¿°ÀÌ´Ù. À̿ܿ¡µµ ·ù¸¶Æ¼½º°üÀý¿°, Åëdz µî ÅëÁõ°ú ¿°ÁõÀÌ ÀúÀý·Î »ý±â´Â ÀÚ°¡¸é¿ª, ÀÚ°¡¿°Áõ ÁúȯµéÀ» Áø·áÇϰí ÀÖ´Ù. EBS ¸íÀÇ ÇÁ·Î±×·¥¿¡ °­Á÷¼ºÃ´Ãß¿°, ·ù¸¶Æ¼½º °üÀý¿°, Åëdz ¸íÀÇ·Î Ã⿬Çß´Ù. ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ, ÇÐȸ »êÇÏ Ã´Ãß°üÀý¿° ¿¬±¸È¸, ·ù¸¶Æ¼½º ¿µ»ó¿¬±¸È¸¿¡¼­ ¿î¿µÀ§¿øÀ» ¸Ã°í, Ȱµ¿°ú ¿¬±¸¸¦ À̾°í ÀÖ´Ù. ÁÖµÈ ±âÃÊ ¿¬±¸ ºÐ¾ß´Â ¿°Áõ°ú »ÀÀÇ ¼Ò½Ç, »ÀÀÇ »ý¼º °úÁ¤ÀÌ´Ù ÀÓ»ó ¿¬±¸´Â Áø·á °æÇèÀ» ¹ÙÅÁÀ¸·Î ÇöÀç±îÁö 20¿© °¡Áö ±Û·Î¹ú ½Å¾à ÀÓ»ó½ÃÇèÀ» ÁøÇàÇÏ¿´°í, ½ÃÇàÇϰí ÀÖ´Ù. ÀÌ»óÈÆ ±³¼ö¸¦ ã´Â °­Á÷¼º ôÃß¿° ȯÀÚ ¼ö´Â 1³â¿¡ 1500¸íÀ» ³Ñ´Â´Ù. ±× ÀÌÀ¯´Â ¹°·Ð Ä¡·á ½Ç·Âµµ ÀÖ°ÚÁö¸¸ ÀÌ»óÈÆ ±³¼ö°¡ °­Á÷¼º ôÃß¿° ȯÀÚÀ̱⠶§¹®ÀÌ´Ù. °í3¿¡ ¹ßº´ÇØ Á¤È®ÇÑ º´¸íÀ» ¾Æ´Â µ¥¸¸ 5³âÀÌ °É·È´Ù. ±×·¡µµ ¿ë±â¸¦ ³»¼­ Ä¡·á¸¦ ¹Þ¾Ò°í Àü°ø±îÁö ·ù¸¶Æ¼½º³»°ú·Î ¼±ÅÃÇß´Ù. °­Á÷¼º ôÃß¿°À» ¾Î´Â Àǻ簡 Áø·á¸¦ º»´Ù´Â ¼Ò¹®ÀÌ ÆÛÁö¸é¼­ ȯÀÚµéÀÌ ÇϳªµÑ ã¾Æ¿À±â ½ÃÀÛÇØ ȯÀÚÀÇ ¸¶À½À» °¡Àå Àß ¾Æ´Â ÀÇ»ç·Î ÀÔ¼Ò¹®À» ¾ò¾ú´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ë ÀÇ´ë Çлç
  • °æÈñ´ë ÀÇ´ë ¼®¹Ú»ç
  • ½ºÅÄÆ÷µå ´ëÇб³ ·Îºó½¼ ¿¬±¸½Ç, ¹æ¹®±³¼ö °­Á÷ôÃß¿° ÀÚ°¡Ç×ü ¿¬±¸

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø QPS ½ÇÀå
  • úÞ) °æÈñ´ëÇб³ Àǰú´ëÇÐ ·ù¸¶Æ¼½º³»°úÇÐ ÁÖÀÓ±³¼ö
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø °üÀý·ù¸¶Æ¼½º³»°ú Áø·á°úÀå
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø °üÀý·ù¸¶Æ¼½º³»°ú ±³¼ö
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø Áø´ÜÄÚµùÀ§¿øÈ¸ À§¿øÀå
  • úÞ) °­µ¿°æÈñ´ëÇб³º´¿ø ÀÇÇבּ¸À±¸®½ÉÀÇȸ °£»ç
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ·ù¸¶Æ¼½º ½Ç½ÀÇРåÀÓ±³¼ö (2015 ~ 2022)

¼ö»ó³»¿ª

Awards List
  • °íȲÀÇÇлó Àº»ó ¼ö»ó ¡°PDCD1 polymorphism in patients with ankylosing spondylitis¡±(2007)

ÇÐȸȰµ¿

Academic activities
  • ´ëÇѳ»°úÇÐȸ ½ÅÆ÷°ý¼ö°¡Á¦À§¿øÈ¸ À§¿ø
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Áø·áÁöħ À§¿øÈ¸ À§¿ø
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ °­Á÷ôÃß¿°(ôÃß°üÀý¿°) ¿¬±¸È¸ Á¤Ã¥È«º¸ °£»ç
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ °üÀýÃÊÀ½ÆÄ ¿¬±¸È¸ ¿î¿µÀ§¿ø
  • ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Á¤È¸¿ø
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Korean treatment recommendations for patients with axial spondyloarthritis
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö The Korean journal of internal medicine
Á¦ ¸ñ Updates on ankylosing spondylitis: pathogenesis and therapeutic agents
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸÁö
Á¦ ¸ñ Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Rheumatology and Therapy
Á¦ ¸ñ Usability and understandability of a web-based medical communication aid for patients with ankylosing spondylitis in South Korea: A mixed-methods study
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Medicine
Á¦ ¸ñ Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö International Journal of Rheumatic Diseases
Á¦ ¸ñ Computed tomography-based assessment of radiographic progression in spine and sacroiliac joints after pregnancy in women with radiographic axial spondyloarthritis
¹ßÇ¥³âµµ 2022 ¹ßÇ¥Áö Frontiers in Medicine
Á¦ ¸ñ Clinical characteristics of non-radiographic axial spondyloarthritis: Results of the Korean Nonradiographic Axial SPondyloArthritis (KONASPA) data
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö International Journal of Rheumatic Diseases.

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

°­Á÷¼º ôÃß¿°ÀÇ ¹ßº´±âÀü, ¾à¹°Ä¡·á·Î ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â ±âÀü¿¡ ´ëÇØ °ü½ÉÀÌ ¸¹À¸¸ç,
°­Á÷¼º ôÃß¿°ÀÇ Áã¸ðµ¨ °³¹ß°ú °ñÇü¼® ±âÀüÀ» ¿¬±¸ÇÏ¿© »õ·Î¿î Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ Èĺ¸ ÀÎÀÚµéÀ»
¹ß±¼Çϰí ÀÖ½À´Ï´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

¸¸¼º ÁúȯÀÎ ¸¸Å­ Ä¡·á¿¡ ´ëÇÑ ¼øÀÀµµ À¯Áö°¡ °¡Àå Áß¿äÇÏ´Ù°í »ý°¢Çϸç,
Ä¡·á ¼øÀÀµµ¸¦ ³ôÀ̱â À§Çؼ­´Â ¾î·Á¿î Àü¹® Áö½ÄÀ» ȯÀÚ ¼öÁØ¿¡¼­ ÀÌÇØÇϱ⠽±°Ô ¼³¸í, »óÈ£ ¼ÒÅë
ÇÏ´Â °ÍÀÌ °¡Àå Áß¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

¸é¿ªÁúȯÀº ÁúȯÀ¸·Î ºÐ·ùÇÏÁö¸¸, ±× °æ°è¿Í ½ºÆåÆ®·³ÀÌ Á¤»ó ±Ùó¿¡¼­ ½ÉÇÑ ÀÌ»ó Á¤µµ±îÁö ¸Å¿ì ´Ù¾çÇÑ ¸ð½ÀÀ» º¸ÀÌ´Â ÀÏÁ¾ÀÇ ¸é¿ª¹ÝÀÀ üÁú·Î ¼³¸íÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸é¿ª¹ÝÀÀÀÇ Á¶ÀýÀº ¾àÀ¸·Î ÃæºÐÈ÷ Á¶ÀýÀÌ °¡´ÉÇÏ¸ç ±×¶§ ±×¶§ ¸é¿ª¹ÝÀÀÀº ´Þ¶óÁö¹Ç·Î Áö¼ÓÀûÀ¸·Î ³ªºüÁö´Â ÅðÇ༺ Áúȯ°ú´Â ´Þ¸® ¾ó¸¶µçÁö Ä¡·á·Î Á¤»ó±â´ÉÀ» À¯ÁöÇÒ ¼ö ÀÖÀ¸¹Ç·Î ³«´ãÇÏÁö ¸¶½Ã°í º´¿ø¿¡¼­ ²ÙÁØÇÑ °ü¸®¸¦ ¹ÞÀ¸½Ã¸é Á¤»óÀκ¸´Ù ´õ °Ç°­ÇÏ°Ô Áö³¾ ¼ö ÀÖ½À´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä